[{"from": "human", "value": "Please give me some details about this molecule. [C][C][=C][C][=C][Branch2][Ring1][Ring1][C][=Branch1][C][=O][N][Ring1][#Branch1][C][=C][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][F][C][=Branch1][C][=O][N][C][=C][C][=Branch2][Ring2][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][O][C][=C][Branch1][#C][C][=C][C][=Branch1][Ring2][=C][Ring1][=Branch1][C][=N][N][Ring1][=Branch1][C][C][=C][N][N][=C][Ring1][Branch1][F]"}, {"from": "gpt", "value": "The molecule is an orally available, small molecule inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor (HGFR)) with potential antineoplastic activity. Merestinib selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. This agent has potent anti-tumor efficacy in mono and combination therapy in a broad range of cancers. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis."}]